Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felicia Cosman

Showing results (71-80 of 117) with videos related to

Pageof 12
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 12, 2018
Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I TrialsTiffany Y Kim, Douglas C Bauer, Brian L McNabb, et al.
The Journal of Clinical Endocrinology and Metabolism|February 23, 2016
Effect of Teriparatide on Bone Formation in the Human Femoral NeckFelicia Cosman, David W Dempster, Jeri W Nieves, et al.
Bone|April 30, 2013
Determinants of stress fracture risk in United States Military Academy cadetsFelicia Cosman, Jamie Ruffing, Marsha Zion, et al.
The Journal of Clinical Endocrinology and Metabolism|September 13, 2014
Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?Felicia Cosman, Jane A Cauley, Richard Eastell, et al.
JBMR Plus|May 11, 2026
Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosisRichard Eastell, Eric Orwoll, Felicia Cosman, et al.
The Journal of Clinical Endocrinology and Metabolism|April 2, 2009
Neuropsychological features in primary hyperparathyroidism: a prospective studyMarcella D Walker, Donald J McMahon, William B Inabnet, et al.
Bone Reports|March 28, 2020
No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patientsBarbara M Misof, Paul Roschger, Hua Zhou, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 24, 2006
A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatideRobert Lindsay, Felicia Cosman, Hua Zhou, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 3, 2012
Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspectiveSteven Boonen, Serge Ferrari, Paul D Miller, et al.
Bone|December 25, 2019
Abnormal microarchitecture and stiffness in postmenopausal women with isolated osteoporosis at the 1/3 radiusAlexander S Dash, Sanchita Agarwal, Donald J McMahon, et al.
Pageof 12

Showing results (71-80 of 117) with videos related to

Sort By:
Pageof 12
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 12, 2018
Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I TrialsTiffany Y Kim, Douglas C Bauer, Brian L McNabb, et al.
The Journal of Clinical Endocrinology and Metabolism|February 23, 2016
Effect of Teriparatide on Bone Formation in the Human Femoral NeckFelicia Cosman, David W Dempster, Jeri W Nieves, et al.
Bone|April 30, 2013
Determinants of stress fracture risk in United States Military Academy cadetsFelicia Cosman, Jamie Ruffing, Marsha Zion, et al.
The Journal of Clinical Endocrinology and Metabolism|September 13, 2014
Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?Felicia Cosman, Jane A Cauley, Richard Eastell, et al.
JBMR Plus|May 11, 2026
Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosisRichard Eastell, Eric Orwoll, Felicia Cosman, et al.
The Journal of Clinical Endocrinology and Metabolism|April 2, 2009
Neuropsychological features in primary hyperparathyroidism: a prospective studyMarcella D Walker, Donald J McMahon, William B Inabnet, et al.
Bone Reports|March 28, 2020
No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patientsBarbara M Misof, Paul Roschger, Hua Zhou, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 24, 2006
A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatideRobert Lindsay, Felicia Cosman, Hua Zhou, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 3, 2012
Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspectiveSteven Boonen, Serge Ferrari, Paul D Miller, et al.
Bone|December 25, 2019
Abnormal microarchitecture and stiffness in postmenopausal women with isolated osteoporosis at the 1/3 radiusAlexander S Dash, Sanchita Agarwal, Donald J McMahon, et al.
Pageof 12